{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"109"}],"units":"Participants"}],"description":"Incidence of Adverse Events CTCAE grade 3 or higher reported","groups":[{"description":"Subjects to receive palifermin before-high dose chemotherapy and matched placebo after-high dose chemotherapy","id":"OG000","title":"Palifermin Before Only"},{"description":"Subjects to receive matched placebo before- and after-high dose chemotherapy","id":"OG001","title":"Placebo"},{"description":"Subjects to receive palifermin before- and after-high dose chemotherapy","id":"OG002","title":"Palifermin Before and After"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at Day 32","title":"Incidence of Adverse Events and Laboratory Abnormalities","type":"SECONDARY","unitOfMeasure":"Participants"}